Original reporting and analysis on the stories shaping biotech.
Roche's experimental obesity drug just posted 15.5% weight loss in a mid-stage diabetes trial, crashing the Novo Nordisk and Eli Lilly duopoly. But can a late entrant with a $5 billion pipeline shopping spree actually compete with the market leaders?
uniQure's Huntington's gene therapy looked like a breakthrough at three years. Then the four-year data arrived, the stock lost $1 billion in value, and the entire promise of gene therapy in brain disease came under scrutiny.
A small biopharma just showed that a once-daily pill can block the same pathway as blockbuster psoriasis injections, with a half-life long enough to support weekly dosing. The proof-of-concept data is early, but in a $30 billion market dominated by needles, it's enough to turn heads.
Roche just announced it's building autonomous AI-driven labs and chasing "AI independence" in drug discovery. With 2,176 NVIDIA GPUs, CHF 2 billion in redirected R&D savings, and an AI tool influencing 80% of research decisions, this is pharma's boldest robot-lab bet yet.
DBV Technologies just submitted its peanut allergy patch for FDA approval, but the backstory is wild: seven years of rejections, redesigns, and regulatory do-overs. With the only competing treatment now off the U.S. market, the stakes have never been higher.
PhRMA just named former House Majority Leader Eric Cantor as its next CEO, choosing a Washington power player over a healthcare insider. With Medicare drug-price negotiations expanding and lobbying spend topping $38 million, the hire tells you exactly where pharma thinks the real battle is.
Lupus has destroyed more drug programs than almost any disease in biotech. Amgen's daxdilimab just posted a clean phase 2 win in discoid lupus, making it one of the rare survivors of the industry's most notorious therapeutic graveyard.
Beam Therapeutics is suing a former scientist and two biotech companies, alleging they stole proprietary base-editing secrets to build a competing gene therapy. The case could reshape how the entire gene-editing industry thinks about protecting its most valuable know-how.
Zealand Pharma's obesity drug petrelintide posted 9.8% weight loss in Phase 2, but with a catch: the middle dose outperformed the highest one. The inverted dose-response curve complicates Phase 3 planning and raises fascinating questions about the limits of amylin biology.
Eli Lilly's retatrutide just became the first triple-agonist obesity drug to post pivotal Phase 3 data, and patients lost up to 20.8% of their body weight. In a $66 billion market that's getting more crowded by the month, Lilly is betting that three biological targets are better than two.
MIT researchers used an AI system to design mRNA vaccine packaging that stays stable at room temperature for a full year, no freezer required. If it works in humans, it could rewrite the rules of global vaccine distribution.
Novo Nordisk is spending up to $2.6 billion on an obesity drug that hasn't been tested in a single human outside China. It sounds reckless, but the logic behind the deal reveals just how desperate the race against Eli Lilly has become.
AstraZeneca is dropping $2 billion for a 12% stake in Summit Therapeutics and the right to test combinations with ivonescimab, a bispecific antibody that's beating Keytruda in lung cancer trials. The real question: is this just the opening act for a $15 billion deal?
Novartis shelled out $12 billion for Avidity Biosciences and its muscle-targeting RNA platform. Then a key Phase 3 trial failed, and Wall Street started asking uncomfortable questions about whether the deal was worth it.
Roche killed its muscle-preserving obesity antibody after it flopped in a mid-stage trial. It's the latest non-GLP-1 approach to crash against an impossibly high bar set by incretin drugs, and it tells us a lot about where the obesity race is really headed.
Telix Pharmaceuticals is spending up to $2.35 billion to acquire ITM Isotope Technologies Munich, the world's largest producer of a critical cancer-fighting isotope. In a sector where supply is scarcer than demand, Telix just bought the factory.
Merck just pulled a critical last-resort antibiotic from the U.S. market while superbugs are surging. The reason says everything about why the antibiotic pipeline is collapsing, and why Congress still hasn't fixed it.
Novartis's pelacarsen and Novo Nordisk's ziltivekimab both nailed their biomarker targets in massive heart disease trials, yet neither drug reduced cardiovascular events. These were supposed to be genetics' greatest hits; instead, they're raising hard questions about what DNA evidence can actually predict.
Novartis's remibrutinib just beat an older MS drug in two large Phase 3 trials, but the real story is *how* it works. Unlike treatments that destroy or trap immune cells, this BTK inhibitor simply tells them to stand down. And in a competitive race littered with safety failures, that distinction could be worth billions.
Merck just dropped $400 million on a Chinese biotech's preclinical cancer drug targeting a protein scientists called "undruggable" for 40 years. The KRAS G12D race is on, and Merck's gamble says everything about where Big Pharma is shopping for its next blockbuster.
Kodiak Sciences failed three consecutive Phase 3 trials and was left for dead. Then its redesigned wet AMD study matched Eylea's efficacy while more than half of patients went six months between injections, nearly tripling the stock overnight.
Two children died in separate gene-editing trials in China, and neither death was promptly disclosed to the public. The fallout is forcing a global reckoning with how experimental therapies reach the most vulnerable patients.
Join thousands of biotech professionals who start their day with our free, daily briefing.